Anti-Angiogenic Therapy in Uveal Melanoma

摘要: For several decades, targeting of tumor-related vessels has been regarded as a potential anticancer therapy. Such anti-angiogenic therapy is based on the assumption that tumor cannot grow beyond limits diffusion (about 1-2 mm) oxygen and nutrients from capillaries, unless angiogenesis takes place. Vascular endothelial growth factor (VEGF) plays key role in angiogenesis, regulating vasopermeability well proliferation migration cells. In types cancer (colon carcinoma, soft tissue sarcomas gastric cancer), serum VEGF levels are marker for disease stage an indicator metastasis. significantly elevated uveal melanoma patients with metastatic compared to without metastases. Anti-angiogenic therapy, such bevacizumab, currently used treatment metastases malignancies. not yet tested primary or related disease. Clinicians, however, have broad experience agents by treating complications radiation We will discuss angiogenic processes molecular pathways melanoma. The use current commercially experimentally available drugs and/or be explained below.